GT Biopharma moves to Withdraw its Form S-1 Registration Statement
DENVER, Colo., Feb 25, 2025 (247marketnews.com)- GT Biopharma (NASDAQ:GTBP) moved to withdraw its Form S-1 Registration Statement (File No. 333-284032), originally filed with the SEC on December 23, 2024. This filing, which had not yet gone effective and involved no securities sales, was poised to raise capital through a public offering. The strategic retreat helps avoid dilution, preserves flexibility, and potentially boosting long-term valuation, GT Biopharma’s move could be a win for its investors.
The immediate boon for GTBP shareholders is the sidestepping of dilution. The S-1, amended on February 7, proposed issuing up to 3,361,344 shares and warrants at $2.38—a 150% increase over the 2.23 million shares outstanding (as of January 9, 2025).
By withdrawing, GTBP preserves its tight float and helps shield shareholders from the value erosion.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (GTBP)
- MoBot alert highlights: NASDAQ: ACRV, NASDAQ: PT, NASDAQ: GTBP, NASDAQ: CLRO, NASDAQ: SWIN (09/05/25 07:00 PM)
- MoBot alert highlights: NASDAQ: ACRV, NASDAQ: PT, NASDAQ: GTBP, NASDAQ: CLRO, NASDAQ: SWIN (09/05/25 06:00 PM)
- MoBot alert highlights: NASDAQ: ACRV, NASDAQ: PT, NASDAQ: GTBP, NASDAQ: CLRO, NASDAQ: SWIN (09/05/25 05:00 PM)
- Breaking News: MoBot’s Latest Update as of 09/05/25 04:00 PM
- GT Biopharma Appoints New Member to its Board of Directors